Jane Street Group LLC Makes New Investment in Pharvaris (NASDAQ:PHVS)

Jane Street Group LLC purchased a new position in Pharvaris (NASDAQ:PHVS) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 28,418 shares of the company’s stock, valued at approximately $526,000. Jane Street Group LLC owned 0.09% of Pharvaris at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of PHVS. HighVista Strategies LLC grew its holdings in Pharvaris by 35.9% in the third quarter. HighVista Strategies LLC now owns 22,768 shares of the company’s stock worth $422,000 after purchasing an additional 6,018 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Pharvaris in the third quarter worth $906,000. State Street Corp acquired a new stake in Pharvaris in the third quarter worth $1,000,000. Patient Square Capital LP acquired a new stake in Pharvaris in the third quarter worth $4,488,000. Finally, Sphera Funds Management LTD. grew its holdings in Pharvaris by 8.9% in the third quarter. Sphera Funds Management LTD. now owns 439,292 shares of the company’s stock worth $8,136,000 after purchasing an additional 36,027 shares during the period.

Pharvaris Trading Down 0.1 %

NASDAQ:PHVS opened at $18.53 on Monday. The stock has a market capitalization of $590.00 million, a price-to-earnings ratio of -6.62 and a beta of -3.17. The firm has a fifty day simple moving average of $20.70 and a two-hundred day simple moving average of $19.36. Pharvaris has a 12 month low of $15.37 and a 12 month high of $33.00.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.